Bavarian Nordic concerned over monkeypox dose splitting: "There is very, very limited data"
This is not the first time the Danish vaccine maker has aired its concerns over a new injection method meant to extend vaccine supply. According to CFO Henrik Juuel, the worry is not over the company bottom line, but rather a lack of data.
by christian bundgaard, translated by daniel pedersen
Bavarian Nordic’s concern over the US Food and Drug Administration’s (FDA), newly approved injection method that splits one monkeypox dose into five is down to a lack of good data supporting the technique, says the company’s chief financial officer, Henrik Juuel, to MedWatch.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
